Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval
EXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug Approval
Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting
Sunshine Biopharma and University of Arizona Publish Significant New Research Findings
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R)
Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)
Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology
Why Sunshine Biopharma (SBFM) Stock Dropped After Hours Today
Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
Sunshine Biopharma Stock Rallies On Canadian Approval For Generic Amoxicillin
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin
Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)
Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea
Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline
Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin
Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)
Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)
Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience
Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections
Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market
Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market
Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year
Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market
Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion
Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering
Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug
Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer
Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year
Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada
Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market
Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT